AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03652194 — intervention group
Intervention type: OTHER
Intervention: study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates
Description: 1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model.
Study NCT01224808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
Study NCT01156064 — intervention group
Intervention type: DEVICE
Intervention: Confocal Laser Endomicroscopy (Pentax/Optiscan)
Description: Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
Study NCT01156064 — intervention group
Intervention type: DEVICE
Intervention: Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)
Description: NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
Study NCT01180179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg once daily
Study NCT01180179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: 40mg once daily
Study NCT00813540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
Study NCT00813540 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study NCT02438358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Study NCT02438358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device
Study NCT01335802 — intervention group
Intervention type: GENETIC
Description: Genetic counseling
Study NCT04555915 — intervention group
Intervention type: OTHER
Intervention: Monitoring of cerebral oxygenation
Description: Modify cardio-respiratory support to avoid cerebral hypoxia
Study NCT05490992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training In-person
Description: Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person.
Study NCT04187027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field therapy device
Description: magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
Study NCT03282032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-lung ventilation
Description: The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1.
Study NCT01901887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Juice
Description: The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
Study NCT01901887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
Study NCT03885921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablet
Study NCT03885921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral tablet
Study NCT03885921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: oral tablet
Study NCT00371319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: 0.06-0.1 mg/kg/day
Study NCT00371319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 2-3 gm/day
Study NCT04395222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.
Study NCT04395222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Anti-thymocyte globulin (ATG) 1.5 mg/kg
Study NCT04395222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Study NCT03483922 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Description: Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
Study NCT00008450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant
Study NCT00008450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT00008450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05259241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: activated partial thrombin time
Description: This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
Study NCT03453476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRP and Fotosan 630
Description: After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
Study NCT04146766 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eHealth
Description: The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
Study NCT04701541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diaphragmatic Ultrasound
Description: Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
Study NCT02074605 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon alpha
Study NCT01220362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 0.125%
Description: Bupivacain 0.125%
Study NCT01220362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 0.125%/Fentanyl 2mcg/ml
Description: Bupivacain 0.125%/Fentanyl 2mcg/ml
Study NCT02011295 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ankle arthroscopy with debridement and microfracture of the OLT
Description: ankle arthroscopy with debridement and microfracture of the OLT
Study NCT02011295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Aspirate injection
Study NCT00008450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT00008450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
Study NCT00008450 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01371032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VideoMiller
Description: Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
Study NCT01371032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
Study NCT02248558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Video
Description: Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
Study NCT02248558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced Video
Description: Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
Study NCT04198532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast bath
Description: Contrast bath (hot and cold therapy)
Study NCT00998244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet - very low carb or low fat
Description: Diet comparison in Gastroesophageal Reflux Disease
Study NCT00998244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet - very low carb or low fat
Description: Diet comparison in Gastroesophageal Reflux Disease
Study NCT04234724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Description: Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Study NCT04234724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Description: Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Study NCT04158193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
Study NCT04158193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks.
Study NCT04198532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast bath
Description: Contrast bath (hot and cold therapy)
Study NCT03989830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second-line chemotherapy
Description: choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
Study NCT03989830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: 7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
Study NCT03823664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory Fitness
Description: Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
Study NCT04111562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cranioplasty
Description: Bone grafts
Study NCT03056443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
Study NCT00190775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
Study NCT04892056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friction Mechanics
Description: anterior segment retraction using elastomeric power chains
Study NCT00190775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
Study NCT04820270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous T regulatory cells
Description: Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
Study NCT01443013 — intervention group
Intervention type: OTHER
Intervention: Renal Transplant
Description: urinary sample at month 3, 6 and 12
Study NCT02859038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront cytoreductive surgery
Description: Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
Study NCT02859038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval debulking surgery
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
Study NCT02160418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Study NCT02160418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Incentives
Study NCT02160418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and Cognitive Incentives
Study NCT02290210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 0.25mg
Study NCT02290210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102 0.5mg
Study NCT02290210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 1.0mg
Study NCT02290210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 2.0mg
Study NCT02290210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01148173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined systemic and intrathecal chemotherapy followed by HD-ASCT
Description: Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
Study NCT04768582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay
Description: The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
Study NCT03993015 — intervention group
Intervention type: OTHER
Intervention: Help to diagnosis software
Description: Help to diagnosis software
Study NCT01675622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
Study NCT01675622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine tablets 10mg and 20mg, oral every 4-6 hours
Study NCT00950989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Study NCT00950989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Study NCT00950989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Study NCT00950989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
Study NCT00950989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
Study NCT00950989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: at least 5 mg per week
Study NCT00950989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: at least 5 mg per week
Study NCT01684657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
Study NCT01039961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod 1 mg
Description: IV infusion
Study NCT01039961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod
Description: IV infusion (dose to be determined based on PK from first dose)
Study NCT01039961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod 15 mg
Description: oral, two 7.5 mg tablets
Study NCT00783367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study